Healthcare

UPMC Enterprises has contributed to a $117m series B round for gene therapy developer Ring Therapeutics.

Topas Therapeutics has almost doubled its series B round to $48m thanks to an extension backed by all of its shareholders.

Cornell-linked dog DNA test developer Embark Veterinary raised the capital in a round led by SoftBank Vision Fund 2 at a $700m post-money valuation.

Imec.xpand has returned to back a series B round for sleep diagnostic developer Onera Health, spun out of Imec.

IP Group is among the investors backing the DDR cancer therapeutics developer’s latest round, which took its total funding to $320m.

Icahn School of Medicine spinout Sema4 has completed a reverse merger with CM Life Sciences to begin trading on the Nasdaq Global Select Market.

Less than a year after raising $72.6m in its series A round, Aerovate Therapeutics has gone public following an IPO worth more than $121m.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

ICL vascular implant spinout Veryan Medical has been bought by medical device firm Otsuka after raising $56m from investors including IP Group.

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.